Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of rhEGF (recombinant human Epidermal Growth Factor) in preparation of medicament for preventing and treating cerebral ischemia

A technology for cerebral ischemia and focal cerebral ischemia, which can be used in application, food preparation, drug combination, etc., and can solve problems such as poor curative effect

Inactive Publication Date: 2015-05-27
TIANJIN GOALGEN BIOTECH
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] Many neuroprotective agents theoretical

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of rhEGF (recombinant human Epidermal Growth Factor) in preparation of medicament for preventing and treating cerebral ischemia
  • Application of rhEGF (recombinant human Epidermal Growth Factor) in preparation of medicament for preventing and treating cerebral ischemia
  • Application of rhEGF (recombinant human Epidermal Growth Factor) in preparation of medicament for preventing and treating cerebral ischemia

Examples

Experimental program
Comparison scheme
Effect test
No Example Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an application of rhEGF (recombinant human Epidermal Growth Factor) in preparation of a medicament or health product for preventing and treating cerebral ischemia. A pharmacological research shows that the rhEGF has a certain treatment effect on acute/chronic ischemic cerebrovascular diseases, and the medicament can pass through a blood brain barrier, is mainly distributed at a cerebral hemisphere, a brain stem and the like, has an effect of relieving spasm of vascular smooth muscles, and can expand small blood vessels, reduce cerebral vascular resistance, increase the cerebral blood flow, protect endothelial cells and improve microcirculation. The medicament can increase cerebral perfusion of a distant part after MCAO (middle cerebral artery occlusion), resist cell apoptosis, protect neurons of the distant part, and reduce lost contact damages, caused by interruption of a nerve fiber conduction path, to brain tissues of the distant part. Therefore, the medicament can play a certain part in clinical prognosis after improvement of apoplexy by reducing brain dysfunctions of the distant part.

Description

technical field [0001] The invention relates to the use of rhEGF in preventing and treating cerebrovascular diseases, in particular to the use of rhEGF in the preparation of medicines for preventing and treating cerebral ischemia. Background technique [0002] Cerebrovascular disease is one of the major diseases that seriously endanger human life and health in the world today. [0003] common diseases and frequently-occurring diseases. Cerebral ischemia is a kind of cerebrovascular accident, and it is a common disease in middle-aged and elderly people. [0004] Diseases are a serious threat to human health and life. In recent years, with the continuous development of science and technology, research on [0005] Scholars' in-depth research on the pathogenesis of cerebral ischemia and the cascade reaction of brain tissue cell damage found that the [0006] Inhibition of apoptosis, reduction of inflammatory response and free radicals and other ways to relieve brain tissue d...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K38/18A23L1/29A61P9/10A23L33/00
Inventor 梁青梁兰邹庆薇郝瑞雪闻家兴王菁于琪顾久莹田雪李姣刘建强
Owner TIANJIN GOALGEN BIOTECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products